Adults hospitalized with COVID-19 who also had kidney or liver disease had a lower risk of dying within 28 days if they received the antiviral remdesivir early, according to a large analysis of U.S. medical claims data published this week in Clinical Infectious Diseases.
The reduction was about 25 percent in patients with kidney disease and about 24 percent in patients with liver disease, compared with matched patients who did not receive the drug. Researchers from the University of Illinois and from Gilead Sciences, which manufactures remdesivir, conducted the study together.
For patients and families, the practical question is narrower than the headline number suggests. This is a retrospective look at insurance and hospital billing records, not a randomized trial, and it does not change any existing treatment recommendation. What it adds is more real-world evidence for a population that clinical trials have historically underrepresented.
The Numbers Behind the Headline Figure
The researchers examined records from 2021 to 2025, according to the summary published by the Center for Infectious Disease Research and Policy at the University of Minnesota.
The kidney cohort included 22,378 patients, split evenly between remdesivir recipients and matched controls, and covered people who had required renal replacement therapy in the year before treatment began. The liver cohort included 5,026 patients, also split evenly, and covered conditions including liver injury, cirrhosis, liver failure, and noninfectious hepatitis. Patients were grouped by whether they needed supplemental oxygen in their first two days in the hospital. Nearly 70 percent of patients in each cohort did.
Among those receiving supplemental oxygen, the risk of 28-day in-hospital death was 25 percent lower in the kidney group and 26 percent lower in the liver group among early remdesivir recipients. The largest single figure came from liver patients who did not require oxygen, where the reduction was 49 percent. Among kidney patients who did not require oxygen, the difference was not statistically significant, meaning the data could not distinguish it from chance.
The variable the researchers emphasize is timing. The benefit was tied to early initiation, not to receiving the drug at any point during a hospital stay.
Claims Data Cannot Settle Cause and Effect
This is an observational study built from administrative records, and that design carries a specific weakness that matters here more than usual.
Doctors decide who gets remdesivir. Those decisions are not random. A clinician may be more inclined to start an antiviral early in a patient who arrived sooner after symptom onset, who was more stable, or who was being treated at a hospital with better staffing and drug availability. Each of those factors independently predicts survival. When treated and untreated patients differ systematically before treatment begins, some of the difference in outcomes belongs to those baseline differences rather than to the drug.
Statistical matching reduces this problem but cannot eliminate it, because claims data records diagnoses and procedures rather than clinical detail. It does not capture how sick a patient looked on arrival, how many days of symptoms preceded admission, or what other treatment decisions were made alongside the antiviral.
The study also measured in-hospital death within 28 days. It did not report on outcomes after discharge or on quality of life. Results were not broken out by variant era, even though the study period spans several years in which both the circulating virus and standard care changed considerably.
The Drugmaker Helped Write the Study
Gilead Sciences, which markets remdesivir under the brand name Veklury, is a co-author institution on this research. That does not invalidate the findings, and disclosure is standard practice, but it is context readers are entitled to when interpreting a favorable result about a company's own product.
The relevant comparison is with independent evidence. Randomized trials of remdesivir in hospitalized COVID-19 patients have produced mixed results over the years, with some showing benefit on time to recovery and others finding no significant mortality effect in broad populations. This new analysis does not resolve that literature. It addresses a narrower question about two specific comorbidity groups.
It is also worth noting what is already settled. The FDA approved remdesivir for use across all stages of liver impairment with no dose adjustment in August 2023, following a pharmacokinetic study in patients with hepatic impairment, as Gilead announced at the time. A month earlier, the agency had extended approval to patients with severe renal impairment, including those on dialysis. The regulatory question is not open, which is part of why this study is described as supporting evidence rather than as a new finding about whether the drug can be used.
Guidance for Patients Has Not Changed
Nothing in this study asks a patient to do anything differently. Remdesivir is given intravenously in a hospital setting, and the decision to use it is made by the treating team based on oxygen requirement, timing since symptom onset, kidney and liver function, and other medications.
For people with chronic kidney or liver disease, the actionable takeaway is upstream of the hospital. Both conditions are on the list of factors that raise the risk of severe COVID-19, which makes early evaluation after symptoms begin more important, not less. Contacting a clinician promptly rather than waiting several days preserves the widest range of treatment options, whether that ends up being an oral antiviral at home or an inpatient decision later.
The researchers noted a monitoring point relevant to anyone receiving the drug. Because remdesivir is metabolized primarily through the liver, they wrote that "hepatic laboratory testing is recommended before and during RDV treatment." That reflects existing labeling rather than a new recommendation.
Readers should not start, stop, or request a specific medication based on a single observational study. Anyone with chronic kidney or liver disease who wants to plan ahead can ask their nephrologist or hepatologist now what the plan would be if they developed COVID-19, which is a more useful conversation than one held from a hospital bed.
Key Questions Answered
What did the study find? Among hospitalized COVID-19 patients with kidney or liver disease, early remdesivir was associated with roughly 25 percent and 24 percent lower risk of death within 28 days, respectively.
Does this prove remdesivir saved lives? No. It is an observational analysis of claims data showing an association. Doctors chose who received the drug, and those choices likely correlate with other factors that affect survival.
How large was the study? 22,378 patients in the kidney cohort and 5,026 in the liver cohort, drawn from records covering 2021 to 2025.
Who funded or conducted it? Researchers from the University of Illinois and from Gilead Sciences, which manufactures the drug, conducted the study together.
Does this change treatment guidance? No. Remdesivir was already approved for use in patients with liver and kidney impairment, and treatment decisions remain with the hospital team.
Which finding was weakest? The reduction among kidney patients who did not require supplemental oxygen was not statistically significant.
What should patients with kidney or liver disease do? Contact a clinician early after COVID-19 symptoms begin rather than waiting, since timing determines which treatment options remain available.
